Business
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company’s Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s dise
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech, Inc.","displaySize":"","headline":null,"caption":"NKGen Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XRU5Bz8FlnWhn7nRqZ2pow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510","width":300,"height":88}},"lazy":false},{"type":"text","content":"SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced an upcoming presentation on Phase 1 clinical data from the Company’s Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will take place in New Orleans, Louisiana from May 13–17, 2025.","length":657,"tagName":"p"},{"type":"text","content":"Presentation Details ","length":20,"tagName":"p"},{"type":"text","content":"Title: Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease. Preliminary Clinical and Biomarker Results.","length":195,"tagName":"p"},{"type":"text","content":"Presenting Author: Paul Y. Song, M.D.","length":42,"tagName":"p"},{"type":"text","content":"Session Details: Gene Therapy Clinical Trials - Oral Presentation","length":70,"tagName":"p"},{"type":"text","content":"Location: NOLA Theater B","length":29,"tagName":"p"},{"type":"text","content":"Presentation Date & Time: Wednesday, May 14, 2025; 2:30–2:45 PM, Central Time","length":86,"tagName":"p"},{"type":"text","content":"Previously disclosed data for troculeucel in Alzheimer’s disease and solid tumors can be found on the Company’s website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company’s website at https://nkgenbiotech.com/news/.","leng...